Connecticut Insurance Department



2024 Pharmacy Benefit Manager Rebate Report Submitted To the Insurance & Real Estate Committee In accordance with CGS §38a-479ppp

March 1, 2024

Pursuant to Connecticut General Statute §38a-479ppp, the Connecticut Insurance Department has provided our 2024 PBM Rebate Report.

The report summarizes Connecticut PBM rebates for calendar 2023 as follows:

- 1. The aggregate dollar amount of all rebates concerning drug formularies used by such health carriers that such manager collected from pharmaceutical manufacturers that manufactured outpatient prescription drugs that were covered by such health carriers during such calendar year and are attributable to patient utilization of such drugs during such calendar year.
- 2. The aggregate dollar amount of all rebates, excluding any portion of the rebates received by such health carriers (i.e., the aggregate amount of the rebates in part 1 that are retained by the PBM), concerning drug formularies that such manager collected from pharmaceutical manufacturers that manufactured outpatient prescription drugs that were covered by such health carriers during such calendar year and attributable to patient utilization of such drugs by covered persons under such health care plans during such calendar year.

The Department compiled the report with data collected from 6 entities and the results are described on the following pages. Please note, this data only represents the PBM rebates for the fully insured market.

We hope you find this report informative.

Respectfully,

Andrew N. Mais Insurance Commissioner

1. The aggregate dollar amount of all rebates concerning drug formularies used by such health carriers that such manager collected from pharmaceutical manufacturers that manufactured outpatient prescription drugs that were covered by such health carriers during such calendar year and are attributable to patient utilization of such drugs during such calendar year.

For Calendar Year 2023: \$442,410,685

2. The aggregate dollar amount of all rebates, excluding any portion of the rebates received by such health carriers (i.e., the aggregate amount of the rebates in part 1 that are retained by the PBM), concerning drug formularies that such manager collected from pharmaceutical manufacturers that manufactured outpatient prescription drugs that were covered by such health carriers during such calendar year and attributable to patient utilization of such drugs by covered persons under such health care plans during such calendar year.

For Calendar Year 2023: \$1,392,681 (0.3%)

In calendar year 2023, PBMs in aggregate, retained 0.3% of all pharmaceutical manufacturer rebates they collected.